Home-based treatment of cellulitis with twice-daily cefazolin

Medical Journal of Australia

Volumn 169, Issue 10, 1998, Pages 519-522

  Leder, Karin ^a   Turnidge, John D ^c   Grayson, M Lindsay ^a,b  

^a MONASH MEDICAL CENTRE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c WOMEN S AND CHILDREN S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFAZOLIN;

ADULT; AGED; ARTICLE; CELLULITIS; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HOME CARE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MINIMUM INHIBITORY CONCENTRATION; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0032538955     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.1998.tb123398.x     Document Type: Article

References (33)

1. Swart MN. Cellulitis and subcutaneous tissue infections. In: Mandell GL, Bennett JE, Dolin R. Principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone, 1994: 914-916.
2. Schwartz R, Das-Young LR, Ramirez-Ronda C. Current and future management of serious skin and skin-structure infections. Am J Med 1996; 100: 90S-95S.
3. Therapeutic guidelines: antibiotic, 10th ed. Melbourne: Therapeutic Guidelines Limited, 1998: 176.
4. Sohn C, Pitkin D, Grappel S, et al. Five cephalosporins: pharmacokinetics and their relation to antibacterial potency. Clin Ther 1984; 6: 560-570.
5. Kucers A, Crowe SM, Grayson ML, Hoy JF. The use of antibiotics: a clinical review of antibacterial, antifungal and antiviral drugs. 5th ed. Oxford: Butterworth Heinemann, 1997: 282-290.
6. Kirby WM, Regamey C. Pharmacokinetics of cefazolin compared with four other cephalosporins. J Infect Dis 1973; 128 Suppl: S341-S346.
7. Cahn MM, Levy EJ, Actor P, Pauls JF. Comparative serum levels and urinary recovery of cefazolin, cephaloridine and cephalothin in man. J Clin Pharmacol 1974; 14: 61-66.
8. Rattie ES, Ravin LJ. Pharmacokinetic interpretation of blood levels and urinary excretion data for cefazolin and cephalothin after intravenous and intramuscular administration in humans. Antimicrob Agents Chemother 1975; 7: 606-613.
9. Gold JA, McKee JJ, Ziv DS. Experience with cefazolin. an overall summary of pharmacologic and clinical trials in man. J Infect Dis 1973; 128 Suppl: S415-S421.
10. Gerber AU. Impact of the antibiotic dosage schedule on efficacy in experimental soft tissue infections. Scand J Infect Dis 1991; Suppl 74: 147-154.
11. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-12.
12. Lorian V. Antibiotics in laboratory medicine. 3rd ed, Baltimore: Williams and Wilkins, 1991: 295-366.
13. Paull PD, Sampson D. Sample preparation for Chromatographic assays in the clinical laboratory. In: Sampson D, editor. High performance liquid chromatography in the clinical laboratory, monograph 2. Sydney: Australian Association of Clinical Biochemists, 1986: 6.
14. Miner DJ. Antibiotics. In: Wong SHY, editor. Therapeutic drug monitoring and toxicology by liquid chromatography. New York: Marcel Dekker, 1985: 269.
15. Gardner MJ, Altman DG. Statistics with confidence. London: British Medical Journal Publications, 1989.
16. Grayson ML, Silvers J, Turnidge J. Home intravenous antibiotic therapy: a safe and effective alternative to inpatient care. Med J Aust 1995; 162: 249-253.
17. Balinsky W, Nesbitt S. Cost-effectiveness of outpatient parenteral antibiotics: a review of the literature. Am J Med 1989; 87: 381-385.
18. Eisenberg JM, Kitz DS. Savings from outpatient antibiotic therapy for osteomyelitis. JAMA 1986; 255: 1584-1588.
19. Craig WA. Antibiotic selection factors and description of a hospital-based outpatient antibiotic therapy program in the USA. Eur J Clin Microbiol Infect Dis 1994; 14: 636-642.
20. Turnidge JD. Pharmacodynamics of beta-lactams. Clin Infect Dis. In press.
21. Slutkin G, Marzouk J, Dall L, Mills J. Comparison of cefonicid and cefazolin for treatment of soft-tissue infections. Rev Infect Dis 1984; 6 Suppl 4: S853-S856.
22. Chan JC. Ampicillin sulbactam versus cefazolin or cefoxitin in the treatment of skin and soft tissue infections of bacterial etiology. Adv Ther 1995; 12: 139-146.
23. Parish LC, Witkowski JA. Ceforanide compared with cefazolin in skin and soft tissue infections. Cutis 1984; 33: 313-315.
24. Brown G, Zemcov SJV, Clarke AM. Effect of probenecid on cefazolin serum concentrations. J Antimicrob Chemother 1993; 31: 1009-1011.
25. Brown G, Chamberlain R, Goulding J, Clarke A. Ceftriaxone versus cefazolin with probenecid for severe skin and soft tissue infections. J Emerg Med 1996; 14: 547-551.
26. Craig WA, Ebert SC. Continuous-infusion of β-lactam antibiotics. Antimicrob Agents Chemother 1992; 36: 2577-2583.
27. Chirurgi VA, Edelstein H, Oster SE, et al. Randomized comparison trial of teicoplanin i.V., teicoplanin i.m., and cefazolin therapy for skin and soft tissue infections caused by gram-positive bacteria. South Med J 1994; 87: 875-880.
28. Eron LJ, Choong HP, Hixon DL, et al. Ceftriaxone therapy of bone and soft tissue infections in hospital and outpatient settings. Antimicrob Agents Chemother 1983; 23: 731-737.
29. Tice AD. Once-daily ceftriaxone outpatient therapy in adults with infections. Chemother 1991; 37(Suppl 3): 7-10.
30. Lindbeck G, Powers R. Cellulitis. Hosp Pract 1993; 28(Suppl 2): 10-14.
31. Gordin FM, Wofsy CB, Mills J. Once-daily ceftriaxone for skin and soft tissue infections. Antimicrob Agents Chemother 1995; 27: 648-649.
32. Goldstein NH, Topiel MS, Ehrlich A, Simon G. A comparative study of ceftriaxone vs. cefazolin in the treatment of cellulitis. Curr Ther Res 1984; 36: 653-657.
33. Bradsher RW, Snow RM. Ceftriaxone treatment of skin and soft tissue infections in a once daily regimen. Am J Med 1984; 77: 63-67.